Literature DB >> 10880264

Mechanisms of CD26/dipeptidyl peptidase IV cytokine-dependent regulation on human activated lymphocytes.

F J Salgado1, E Vela, M Martín, R Franco, M Nogueira, O J Cordero.   

Abstract

Among the cellular pathways activated by IL-12, we had previously found that both the percentage and intensity of CD26(+)cells in the PHA-stimulated T cells increased when IL-12 was present (independently of its CD4 or CD8 phenotype). Now, we examined the molecular mechanisms of this IL-12-mediated effect. The IL-12 regulation pathway is dependent of de novo protein synthesis and independent of cytokine secretion. Our results show two transcripts for CD26 in PBMC for the first time and no regulation by ILs at this level. Furthermore, secretion of the serum forms of CD26/DPPIV were not affected by IL-12. Interestingly, assays with neutralizing mAbs against TNF-alpha suggest that this cytokine negatively modulates CD26 expression. The fact that translation and probably translocation of CD26 toward the cell surface can be regulated by IL-12 and TNF-alpha reveals new aspects about the control of this T(H1)marker. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880264     DOI: 10.1006/cyto.1999.0643

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  15 in total

1.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.

Authors:  Jixin Zhong; Saumya Kankanala; Sanjay Rajagopalan
Journal:  Curr Opin Lipidol       Date:  2016-10       Impact factor: 4.776

Review 3.  DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.

Authors:  Jixin Zhong; Andrei Maiseyeu; Stephen N Davis; Sanjay Rajagopalan
Journal:  Circ Res       Date:  2015-04-10       Impact factor: 17.367

4.  Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways.

Authors:  Su-Jin Kim; Cuilan Nian; Christopher H S McIntosh
Journal:  Diabetes       Date:  2010-04-05       Impact factor: 9.461

5.  CD26 expression on CD4+T cells in patients with cutaneous leishmaniasis.

Authors:  R Jafari-Shakib; S Ajdary; Z Mohtasham Amiri; A M Mohammadi; K Nourijelyani; H Mortazavi; M A Shokrgozar; B Nikbin; A Khamesipour
Journal:  Clin Exp Immunol       Date:  2008-05-05       Impact factor: 4.330

Review 6.  Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis?

Authors:  Aleksi Sedo; Jonathan S Duke-Cohan; Eva Balaziova; Liliana R Sedova
Journal:  Arthritis Res Ther       Date:  2005-10-26       Impact factor: 5.156

Review 7.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

8.  Soluble CD26 is inversely Associated with Disease Severity in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Osamu Matsuno; Eishi Miyazaki; Shinichi Nureki; Takuya Ueno; Masaru Ando; Toshihide Kumamoto
Journal:  Biomark Insights       Date:  2007-02-07

Review 9.  DPP4 in Diabetes.

Authors:  Diana Röhrborn; Nina Wronkowitz; Juergen Eckel
Journal:  Front Immunol       Date:  2015-07-27       Impact factor: 7.561

10.  Evaluation of pleural effusion sCD26 and DPP-IV as diagnostic biomarkers in lung disease.

Authors:  Nuria Sánchez-Otero; Francisco Javier Rodríguez-Berrocal; María Páez de la Cadena; María Isabel Botana-Rial; Oscar J Cordero
Journal:  Sci Rep       Date:  2014-02-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.